Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating

Oppenheimer has initiated coverage on Ocugen (OCGN), a biotechnology company focused on gene therapies and vaccines, with a Buy rating, which could signal potential growth opportunities based on their analysis. However, such ratings are common in the sector and may not lead to immediate stock price increases if the market has already anticipated this move or if broader economic factors like inflation and interest rates pose headwinds. Investors should verify the underlying fundamentals, as analyst opinions can be influenced by promotional biases.